Young Alexander Mildner wanted to be an artist. His parents did not object to the idea but suggested that their son should first go to the University of Göttingen, from where he could transfer to an art school after a year. But things turned out differently. Today, Mildner is one of the world's most cited immunology researchers and an Associate Professor at the InFLAMES flagship of the University of Turku.
An international team of researchers has discovered how the so-called tertiary lymphoid-like structures can help the human immune defence to find cancer cells and destroy them. Researchers from the InFLAMES research flagship of the University of Turku, Finland, participated in the study and the research article was published in the esteemed Cancer Cell journal.
The Hospital District of Southwest Finland has chosen the Turku Immunology Centre as its unit of excellence. The Centre, which was established at the end of 2021, was also selected to the Roadmap for Research Infrastructures of the University of Turku.
New discovery on the causes of PAP lung disease can also offer solutions for treating obesity and heart disease. The research group of Associate Professor Alexander Mildner at the University of Turku, Finland, identified a genetic defect that causes the accumulation of lipids in the pulmonary alveoli.
The theme of this year’s BioCity Symposium, immunology, has sparked great interest. Over 400 people have registered for the Symposium that is organised on 25–26 August. The keynote speaker is Sir Peter Ratcliffe, the Nobel Prize Laureate in medicine 2019.
InFLAMES (Innovation Ecosystem based on the Immune System) is a Finnish research flagship that aims at identifying novel drug targets using the most modern technological platforms and finding novel diagnostic tools to identify the patients benefitting from personalised therapies.
Professor and Chief Physician, InFLAMES group leader Pirjo Nuutila is receiving the 2022 Novo Nordisk Foundation Lecture prize for her contribution to research on metabolic diseases such as overweight and diabetes.
InFLAMES (Innovation Ecosystem based on the Immune System) is a Finnish research flagship that aims at identifying novel drug targets using the most modern technological platforms and finding novel diagnostic tools to identify the patients benefitting from personalised therapies.
InFLAMES (Innovation Ecosystem based on the Immune System) is a Finnish research flagship that aims at identifying novel drug targets using the most modern technological platforms and finding novel diagnostic tools to identify the patients benefitting from personalised therapies.
InFLAMES (Innovation Ecosystem based on the Immune System) is a Finnish research flagship that aims at identifying novel drug targets using the most modern technological platforms and finding novel diagnostic tools to identify the patients benefitting from personalised therapies.